États-Unis · Plateformes & données · Stocktwits

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Publié par Stocktwits · États-Unis il y a 14 h

Résumé détaillé

Candel said it is in continuing dialogue with the FDA regarding the Biologics License Application (BLA) submission for aglatimagene in intermediate- to high-risk localized…

Lire l'article complet sur Stocktwits Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stocktwits.com)

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Résumé détaillé

À lire aussi

Recruit Holdings GAAP EPS of ¥159.54, revenue of ¥1.09T

Kodiak Sciences (NASDAQ:KOD) Issues Earnings Results, Beats Estimates By $0.01 EPS

How the Jensen Huang affair changes the outlook for U.S.-China relations

Matador Resources chairman and CEO buys $123,225 in stock

DeSantis Asks How Congress Members With 'No Investment Acumen' Outperform Warren Buffett — 'Oh You Just Happened to Buy Something…Then It Goes Up 150%'

Who can replace Jensen Huang as Nvidia CEO? These four names are buzzing in AI circles.

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Résumé détaillé

Partager

À lire aussi

Recruit Holdings GAAP EPS of ¥159.54, revenue of ¥1.09T

Kodiak Sciences (NASDAQ:KOD) Issues Earnings Results, Beats Estimates By $0.01 EPS

How the Jensen Huang affair changes the outlook for U.S.-China relations

Matador Resources chairman and CEO buys $123,225 in stock

DeSantis Asks How Congress Members With 'No Investment Acumen' Outperform Warren Buffett — 'Oh You Just Happened to Buy Something…Then It Goes Up 150%'

Who can replace Jensen Huang as Nvidia CEO? These four names are buzzing in AI circles.